News Category: Earnings News

– Study Did Not Meet Primary Endpoint SAN DIEGO –(BUSINESS WIRE)–Mar. 11, 2024– Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced top-line results from the Phase 3 ADVANCE-2 trial evaluating pimavanserin for the treatment of negative symptoms of schizophrenia.

– 2023 total net product sales of $726.4 million , reflecting 40% revenue growth. – Fourth quarter DAYBUE ™ (trofinetide) net product sales of $87.1 million and full year 2023 net product sales of $177.2 million . – Fourth quarter NUPLAZID ® (pimavanserin) net product sales of $143.9 million and

– Company reports record revenues resulting from strong DAYBUE launch and growth in NUPLAZID franchise – 3Q23 DAYBUE ™ (trofinetide) net product sales of $66.9 million   – 3Q23 NUPLAZID ® (pimavanserin) net product sales of $144.8 million   SAN DIEGO –(BUSINESS WIRE)–Nov.

– 2Q23 DAYBUE ™ (trofinetide) net product sales of $23.2 million – 2Q23 NUPLAZID ® (pimavanserin) net product sales of $142.0 million – Expanded licensing agreement for trofinetide includes ex-North American rights SAN DIEGO –(BUSINESS WIRE)–Aug. 2, 2023– Acadia Pharmaceuticals Inc.

– 1Q23 NUPLAZID ® net sales of $118.5 million – Announced the U.S. FDA Approval of DAYBUE™ (trofinetide) for the Treatment of Rett Syndrome in Adult and Pediatric Patients Two Years of Age and Older on March 10, 2023 – Announced DAYBUE Availability on April 17, 2023 SAN DIEGO –(BUSINESS WIRE)–May

– Full year 2022 net sales of $517.2 million , an increase of 7% over 2021 – Prescription Drug User Fee Act (PDUFA) action date set for March 12, 2023 , for trofinetide for the treatment of Rett syndrome SAN DIEGO –(BUSINESS WIRE)–Feb. 27, 2023– Acadia Pharmaceuticals Inc.

– 3Q22 net sales of $130.7 million – Prescription Drug User Fee Act action date set for March 12, 2023   for trofinetide for the treatment of Rett syndrome SAN DIEGO –(BUSINESS WIRE)–Nov. 2, 2022– Acadia Pharmaceuticals Inc. (Nasdaq: ACAD), today announced its financial results for the third

– 2Q22 net sales of $134.6 million , a 17% increase over 2Q21 – NDA submitted for trofinetide for the treatment of Rett syndrome SAN DIEGO –(BUSINESS WIRE)–Aug. 8, 2022– Acadia Pharmaceuticals Inc. (Nasdaq: ACAD), today announced its financial results for the second quarter ended June 30, 2022 .

– 1Q22 net sales of $115.5 million , an 8% increase over 1Q21 – Reiterating FY22 net sales guidance of $510 to $560 million – FDA Advisory Committee meeting to review sNDA for pimavanserin for the treatment of ADP scheduled for June 17, 2022 SAN DIEGO –(BUSINESS WIRE)–May 4, 2022– Acadia

SAN DIEGO –(BUSINESS WIRE)–Apr. 18, 2022– Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced top-line results from a Phase 2 randomized, double-blind, placebo-controlled clinical trial evaluating the efficacy and safety of ACP-044 for acute pain following bunionectomy surgery.